Skip to main content

Table 1 The laboratory data on admission

From: A 5-year recurrence-free survivor with over ten colorectal liver metastases undergoing FOLFOX plus bevacizumab followed by two-stage hepatectomy

WBC 7.5 ×103/μl, BUN 11.2 mg/dl
RBC 4.95 ×106/μl Creatinine 0.63 mg/dl
Hemoglobin 16.3 g/dL Amylase 78 U/l
Hematocrit 48.6 % Cholinesterase 270 U/l
Platelet 259 ×103/μl Na 141 mEq/l
PT activity 101 % K 4.1 mEq/l
AST 21 U/l Cl 106 mEq/l
ALT 12 U/l CRP 0.38 mg/dl
ALP 428 U/l Glucose 91 mg/dl
LDH 245 U/l HbA1c 5.3 %
γ-GTP 20 U/l CEA 189.1 ng/ml
Total bile acid 0.6 μmol/l CA19-9 723.0 U/ml
Total protein 7.3 g/dl HBs-Ag (−)  
Albumin 4.3 g/dl HCV-Ab (−)  
  1. WBC white blood cell, RBC red blood cell, PT prothrombin time, AST aspartate aminotransferases, ALT alanine aminotransferases, ALP alkali phosphatase, LDH lactate dehydrogenase, γ-GTP γ-glutamyltransferase, BUN blood urea nitrogen, CRP C-reactive protein, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19–9, HBs-Ag hepatitis B surface antigen, HCV-Ab anti-hepatitis C antibody